← Back to Clinical Trials
Recruiting NCT07255430

NCT07255430 Airway Microbiome of Patients With Protracted Bacterial Bronchitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07255430
Status Recruiting
Phase
Sponsor University Hospital, Antwerp
Condition Protracted Bacterial Bronchitis
Study Type OBSERVATIONAL
Enrollment 160 participants
Start Date 2026-01-07
Primary Completion 2028-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 5 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 160 participants in total. It began in 2026-01-07 with a primary completion date of 2028-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project aims to assess the relationship between the microbiome and virome composition, the immune responses, and the respiratory health of children with protracted bacterial bronchitis (PBB). In addition, we aim to evaluate how the standard treatment with azithromycin interacts with the components of the microbiome, virome and immune biomarkers.

Eligibility Criteria

Inclusion Criteria: * Children with PBB diagnosis according to case definition * Consent form signed by parents or legal guardians Exclusion Criteria: * Comorbidities (HIV, asthma, chronic obstructive pulmonary disease, diabetes) * Have had serious illnesses (meningitis, pneumonia, bacteremia, empyema, etc) in the previous three months, identified only at the time of enrollment. * Have chronic respiratory conditions at the time of enrollment (non-PBB bronchiectasis not caused by PBB, CF, allergy, etc.). * Having received mechanical ventilation. * Having been hospitalized or used antibiotics in the previous three months at the time of enrollment.

Contact & Investigator

Central Contact

Kim Van Hoorenbeeck, Prof. dr.

✉ kim.vanhoorenbeeck@uza.be

📞 +3238213000

Principal Investigator

Kim Van Hoorenbeeck, Prof. dr.

PRINCIPAL INVESTIGATOR

University Hospital, Antwerp

Frequently Asked Questions

Who can join the NCT07255430 clinical trial?

This trial is open to participants of all sexes, up to 5 Years, studying Protracted Bacterial Bronchitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07255430 currently recruiting?

Yes, NCT07255430 is actively recruiting participants. Contact the research team at kim.vanhoorenbeeck@uza.be for enrollment information.

Where is the NCT07255430 trial being conducted?

This trial is being conducted at Edegem, Belgium.

Who is sponsoring the NCT07255430 clinical trial?

NCT07255430 is sponsored by University Hospital, Antwerp. The principal investigator is Kim Van Hoorenbeeck, Prof. dr. at University Hospital, Antwerp. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology